Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females

Authors: Jainagul Isakova, Elnura Talaibekova, Nazira Aldasheva, Denis Vinnikov, Almaz Aldashev

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

The association of genes XRCC1, TP53 and MDM2 with breast cancer (BC) has never been tested in Kyrgyz population. We, therefore, aimed to identify an association of alleles and genotypes of polymorphic markers Arg399Gln of gene XRCC1, Arg72Pro of gene TP53, and T309G of gene MDM2 with the risk of BC in Kyrgyz women.

Methods

This was a case-control study of 219 women of Kyrgyz origin with morphologically verified BC (N = 117) and 102 controls, age-matched with BC cases. The mean age of subjects in this study was 52.2 ± 10.8 years. We extracted DNA from the venous blood and genotyped polymorphic markers Arg399Gln of gene XRCC1, Arg72Pro of gene TP53 and T309G of gene MDM2 using polymerase chain reaction and the method of restriction fragment polymorphism.

Results

Allele 399Gln (OR 1.57; 95% CI 1.05–2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60–4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57–10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18–7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18–34.63) were associated with BC in Kyrgyz women.

Conclusions

This is the first study to identify the inter-loci interaction and to find molecular markers of individual risk of BC in Kyrgyz women.
Literature
1.
Igisinov N, Kokteubaeva N, Kudaibergenova I. Epidemiology of breast cancer in females of reproductive age in Kyrgyzstan. Asian Pac J Cancer Prev. 2005;6:36–9.
2.
Duell EJ, Millikan RC, Pittman GS, Winkel S, Lunn RM, Chiu-Kit JT, et al. Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol. Prev. Biomarkers. 2001;10:217–22.
3.
Lacroix M, Toillon R-A, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006;13:293–325.CrossRefPubMed
4.
Luo H, Li Z, Qing Y, Zhang S-H, Peng Y, Li Q, et al. Single nucleotide polymorphisms of DNA base-excision repair genes (APE1, OGG1 and XRCC1) associated with breast cancer risk in a Chinese population. Asian Pac J Cancer Prev. 2014;15:1133–40.CrossRefPubMed
5.
Bu T, Liu L, Sun Y, Zhao L, Peng Y, Zhou S, et al. XRCC1 Arg399Gln polymorphism confers risk of breast cancer in American population: a meta-analysis of 10846 cases and 11723 controls. PLoS One. 2014;9:e86086.CrossRefPubMedPubMedCentral
6.
Romanowicz H, Smolarz B, Baszczyński J, Zadrożny M, Kulig A. Genetics polymorphism in DNA repair genes by base excision repair pathway (XRCC1) and homologous recombination (XRCC2 and RAD51) and the risk of breast carcinoma in the polish population. Pol J Pathol. 2010;61:206–12.PubMed
7.
Ramadan RA, Desouky LM, Elnaggar MA, Moaaz M, Elsherif AM. Association of DNA repair genes XRCC1 (Arg399Gln),(Arg194Trp) and XRCC3 (Thr241Met) polymorphisms with the risk of breast cancer: a case–control study in Egypt. Genet Test Mol Biomark. 2014;18:754–60.CrossRef
8.
Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7:961–3.CrossRefPubMedPubMedCentral
9.
Dumont P, Leu J-J, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–65.CrossRefPubMed
10.
11.
Leu J-D, Wang C-Y, Tsai H-Y, Lin I, Chen R-C, Lee Y-J. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer. Oncol Rep. 2011;25:1755–63.PubMed
12.
Sun Y-F, Leu J-D, Chen S-M, Lin I-F, Lee Y-J. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer. 2009;9:13.CrossRefPubMedPubMedCentral
13.
Lum SS, Chua HW, Li H, Li W-F, Rao N, Wei J, et al. MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis. 2008;29:754–61.CrossRefPubMed
14.
Mathew CC. The isolation of high molecular weight eukaryotic DNA. Methods Mol Biol. 1984;2:31–4.
15.
Demokan S, Demir D, Suoglu Y, Kiyak E, Akar U, Dalay N. Polymorphisms of the XRCC1 DNA repair gene in head and neck cancer. Pathol Oncol Res. 2005;11:22–5.CrossRefPubMed
16.
Onrat ST, Ellidokuz E, Kupelioglu A, Durhan E. Frequency of TP53 codon72 polymorphism in cases with colon cancer. Turk. J. Cancer. 2009;39:005–10.
17.
Joshi AM, Budhathoki S, Ohnaka K, Mibu R, Tanaka M, Kakeji Y, et al. TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka colorectal cancer study. Jpn J Clin Oncol. 2011;41:232–8.CrossRefPubMed
18.
Proestling K, Hebar A, Pruckner N, Marton E, Vinatzer U, Schreiber M. The pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. PLoS One. 2012;7:e47325.CrossRefPubMedPubMedCentral
19.
Huang X-E, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, et al. Association ofp53 codon arg72pro andp73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of japanese breast cancer. Breast Cancer. 2003;10:307–11.CrossRefPubMed
20.
Ohayon T, Gershoni-Baruch R, Papa MZ, Menachem TD, Barzilai SE, Friedman E. The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer. 2005;92:1144–8.CrossRefPubMedPubMedCentral
21.
Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996;17:1313–6.CrossRefPubMed
22.
Ma Y, Yang J, Liu Z, Zhang P, Yang Z, Wang Y, et al. No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. Breast Cancer Res Treat. 2011;125:201–5.CrossRefPubMed
23.
Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y, et al. P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case–control studies. Breast Cancer Res Treat. 2010;120:509–17.CrossRefPubMed
24.
Gao J, Kang A-J, Lin S, Dai Z-J, Zhang S-Q, Liu D, et al. Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls. Ther Clin Risk Manag. 2014;10:269–77.PubMedPubMedCentral
Metadata
Title
The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females
Authors
Jainagul Isakova
Elnura Talaibekova
Nazira Aldasheva
Denis Vinnikov
Almaz Aldashev
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3762-y

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study

Case report

Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report

Research article

Innovative dressing and securement of tunneled central venous access devices in pediatrics: a pilot randomized controlled trial

Research article

Reduced RCE1 expression predicts poor prognosis of colorectal carcinoma

Research article

Role of peptidylarginine deiminase 2 (PAD2) in mammary carcinoma cell migration

Study protocol

Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits